Icoria’s decision to sell off its agricultural component to Monsanto in order to focus on genomics last week has triggered other changes at the RTP based firm.

Board members Robert Goodman, Susan Harlander and Michael Summers will either resign or not seek re-election in May, Icoria said.

Icoria (Nasdaq: ICOR) also said that it had created an “office of the president” to oversee the transition of the company. Assisting Chief Executive Officer and President Heiri Gugger will be Doug Morton, a member of the board who also is CEO of Southwest Michigan Innovation Center, and Keith Davis, Icoria’s vice president of agricultural biotechnology.

“Doug’s experience in healthcare and specifically in drug development while at Pfizer and Pharmacia will be extremely useful to Icoria as we reposition the business to focus on biomarker-enabled drug discovery,” said Steve Burrill, chairman of Icoria’s board. “The board appreciates Doug’s willingness to assume this critical role during this important transition period.”

Icoria also named Brett Farabaugh as vice president of finance. His previous title had been senior director of finance and chief accounting officer. Phil Alfano left as chief financial officer last year.

Peter Johnson, the firm’s chief medical officer, is leaving “for personal reasons and to pursue other interests,” the company added.

Icoria changed its name from Paradigm Genetics last August.

Icoria stock closed down 5 cents at 34 cents on Wednesday.

Icoria: www.icoria.com